Entering text into the input field will update the search result below

Frequency Therapeutics: FX-322 Top Line Data From Exploratory Study Proves Promising

Jun. 01, 2020 12:33 AM ETFrequency Therapeutics, Inc. (FREQ)14 Comments
Noah Riley profile picture
Noah Riley


  • Frequency Therapeutics reported its first-quarter 2020 results displaying continued ample liquidity.
  • The company simultaneously updated the market with promising results for FX-322 from its exploratory study.
  • FX-322, which aims to tackle sensorineural hearing loss, offers huge upside opportunity as it has the ability to offer a solution to a large market.
  • FX-322 is currently in phase 2a of its trial and expects to report top line data in H2 2020.

Frequency Therapeutics (NASDAQ:FREQ), which is a biotechnology company that focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, most recently reported its first-quarter results and provided top line data from its exploratory study. The top line data confirmed that FX-322 was delivered to the intended target within the cochlea with drug levels that could be directly measured, while it was also predicted to result in therapeutic activity. This can be seen as promising initial results from the company's exploratory study conducted in Germany. This means that one of the key elements in FX-322 development has been met, which is the effective delivery to the target tissue, as outlined in the company's May update presentation. I remain bullish on the prospects of FX-322 and how transformative it can be for both hearing loss and for Frequency Therapeutics as an entity.

The company CEO and co-founder David Lucchino highlighted the importance of this milestone in the Q4 report:

“The cochlea is one of the most privileged and difficult-to-reach sites in the body. Quantifying drug concentrations of a potential restorative medicine in the cochlea represents an important advance in inner-ear drug discovery,”

Mr. Lucchino continued:

“This advance furthers Frequency’s leadership in hearing regeneration and our enthusiasm for the potential of FX-322 to benefit the millions of individuals suffering from sensorineural hearing loss.”

Carl Lebel, chief development officer, also highlighted the significance of these findings:

“When we consider these new findings, together with the hearing signal observed in our earlier Phase 1/2 study, we believe we have developed the first known evidence of a pharmacokinetic/pharmacodynamic effect of a potential hearing restoration therapeutic.”

It is clear to see that FX-322 has continued to deliver so far in its relative tests; Phase 1/2 study and then

This article was written by

Noah Riley profile picture
Hi there! I am Noah, an undergraduate at the University of York in the UK where I also take on the Chief Investment Officer role at the student-led fund. I primarily cover US and UK equities.If you want to reach out, whether that's to ask me any questions or just to connect, feel free to message me on Seeking Alpha or LinkedIn.

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.